We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and biotechnology company focused on developing and commercializing white label...
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing...
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing...
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label...
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing...
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.13 | -47.3333333333 | 4.5 | 5.14 | 2.23 | 402810 | 3.79432035 | CS |
4 | 0.75 | 46.2962962963 | 1.62 | 5.5 | 1.42 | 1002157 | 3.82971606 | CS |
12 | -1.63 | -40.75 | 4 | 5.5 | 1.42 | 583931 | 3.76092875 | CS |
26 | -1.63 | -40.75 | 4 | 5.5 | 1.42 | 583931 | 3.76092875 | CS |
52 | -1.63 | -40.75 | 4 | 5.5 | 1.42 | 583931 | 3.76092875 | CS |
156 | -1.63 | -40.75 | 4 | 5.5 | 1.42 | 583931 | 3.76092875 | CS |
260 | -1.63 | -40.75 | 4 | 5.5 | 1.42 | 583931 | 3.76092875 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions